SCHEMBL4334719

SCHEMBL4334719

COc1ccc(F)cc1-c1cccc(C(=O)O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.54
MAPK1 P28482 1/20 0.53
HTT P42858 1/20 0.53
RAB9A P51151 1/20 0.53
RELA Q04206 3/20 0.52
CTSA P10619 3/20 0.50
MRGPRX4 Q96LA9 2/20 0.50
PDE4A P27815 1/20 0.50
PDE4B Q07343 1/20 0.50
PDE4C Q08493 1/20 0.50
PDE4D Q08499 1/20 0.50
ERN1 O75460 2/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA4 P22748 1/20 0.49
CA6 P23280 1/20 0.49
CA7 P43166 1/20 0.49
TPMT P51580 1/20 0.49
CA9 Q16790 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21880568 0.89 LMNA (0.56) LMNAMAPK1HTTRAB9ARELA
SCHEMBL417159 0.85 KAT6A (0.61) LMNAMAPK1HTTRAB9AMRGPRX4
SCHEMBL14879938 0.84 MRGPRX4 (0.54) LMNAMAPK1HTTRAB9ARELA
SCHEMBL4602802 0.84 HDAC4 (0.62) LMNARAB9ACTSAMRGPRX4PDE4A
SCHEMBL17799599 0.84 KAT6A (0.63) LMNAMAPK1HTTRAB9AMRGPRX4
SCHEMBL2406330 0.83 PTGER1 (0.59) CTSAMRGPRX4PDE4D
SCHEMBL30516742 0.82 CTSA (0.53) LMNAMAPK1HTTRAB9ACTSA
SCHEMBL6608193 0.80 SYK (0.52) LMNARAB9ACTSAERN1CA12
SCHEMBL5149280 0.79 LMNA (0.69) LMNAMAPK1HTTRAB9AMRGPRX4
SCHEMBL4063179 0.79 STIM1 (0.64) CTSAMRGPRX4PDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK LMNA 4580/4885MAPK1 1691/4885HTT 224/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK LMNA 4580/4885MAPK1 1691/4885HTT 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.